News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
727,690 Results
Type
Article (41209)
Company Profile (264)
Press Release (686201)
Multimedia
Podcasts (88)
Webinars (20)
Section
Business (204777)
Career Advice (2028)
Deals (35561)
Drug Delivery (126)
Drug Development (81474)
Employer Resources (173)
FDA (16479)
Job Trends (14970)
News (346680)
Policy (32750)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (2592)
Accelerated approval (43)
Adcomms (25)
Allergies (165)
Alliances (49578)
ALS (197)
Alzheimer's disease (1755)
Antibody-drug conjugate (ADC) (412)
Approvals (16824)
Artificial intelligence (617)
Autoimmune disease (240)
Automation (52)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (210)
Biotechnology (174)
Bladder cancer (182)
Brain cancer (68)
Breast cancer (703)
Cancer (5522)
Cardiovascular disease (453)
Career advice (1718)
Career pathing (41)
CAR-T (309)
CDC (54)
Celiac Disease (2)
Cell therapy (815)
Cervical cancer (43)
Clinical research (70412)
Collaboration (1974)
Company closure (4)
Compensation (1315)
Complete response letters (75)
COVID-19 (2732)
CRISPR (100)
C-suite (1033)
Cystic fibrosis (149)
Data (7322)
Decentralized trials (3)
Denatured (26)
Depression (155)
Dermatology (70)
Diabetes (554)
Diagnostics (6871)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (303)
Drug pricing (195)
Drug shortages (31)
Duchenne muscular dystrophy (268)
Earnings (91187)
Editorial (63)
Employer branding (21)
Employer resources (152)
Events (118725)
Executive appointments (1049)
FDA (20010)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (33)
Funding (1655)
Gene editing (215)
Generative AI (54)
Gene therapy (664)
GLP-1 (1026)
Government (4709)
Grass and pollen (6)
Guidances (401)
Healthcare (18961)
HIV (76)
Huntington's disease (52)
IgA nephropathy (93)
Immunology and inflammation (276)
Immuno-oncology (85)
Indications (166)
Infectious disease (3061)
Inflammatory bowel disease (204)
Inflation Reduction Act (14)
Influenza (133)
Intellectual property (277)
Interviews (316)
IPO (16655)
IRA (50)
Job creations (3646)
Job search strategy (1430)
JPM (58)
Kidney cancer (18)
Labor market (94)
Layoffs (557)
Leadership (35)
Legal (7951)
Liver cancer (98)
Longevity (30)
Lung cancer (740)
Lymphoma (413)
Machine learning (55)
Management (59)
Manufacturing (960)
MASH (178)
Medical device (13878)
Medtech (13961)
Mergers & acquisitions (20097)
Metabolic disorders (1429)
mRNA (185)
Multiple sclerosis (178)
NASH (17)
Neurodegenerative disease (386)
Neuropsychiatric disorders (99)
Neuroscience (3184)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4525)
Now hiring (74)
Obesity (673)
Opinion (280)
Ovarian cancer (198)
Pain (240)
Pancreatic cancer (269)
Parkinson's disease (347)
Partnered (33)
Patents (563)
Patient recruitment (620)
Peanut (61)
People (59366)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (21948)
Phase 2 (31005)
Phase 3 (23078)
Pipeline (7541)
Policy (306)
Postmarket research (2566)
Preclinical (9333)
Press Release (64)
Prostate cancer (282)
Psychedelics (50)
Radiopharmaceuticals (313)
Rare diseases (1010)
Real estate (5961)
Recruiting (70)
Regulatory (25118)
Reports (54)
Research institute (2409)
Resumes & cover letters (353)
Rett syndrome (34)
RNA editing (19)
RSV (88)
Schizophrenia (168)
Series A (273)
Series B (206)
Service/supplier (11)
Sickle cell disease (108)
Special edition (22)
Spinal muscular atrophy (164)
Sponsored (46)
Startups (3628)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (60)
Vaccines (1069)
Venture capital (100)
Weight loss (432)
Women's health (114)
Worklife (20)
Date
Today (130)
Last 7 days (722)
Last 30 days (2685)
Last 365 days (30319)
2026 (9424)
2025 (30171)
2024 (35212)
2023 (40075)
2022 (51174)
2021 (55709)
2020 (54084)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (738)
Alabama (91)
Alaska (7)
Arizona (337)
Arkansas (14)
Asia (39537)
Australia (6475)
California (12551)
Canada (3612)
China (1267)
Colorado (539)
Connecticut (544)
Delaware (378)
Europe (85421)
Florida (1887)
Georgia (403)
Hawaii (3)
Idaho (62)
Illinois (997)
India (86)
Indiana (576)
Iowa (23)
Japan (508)
Kansas (129)
Kentucky (46)
Louisiana (38)
Maine (75)
Maryland (1509)
Massachusetts (8956)
Michigan (350)
Minnesota (687)
Mississippi (6)
Missouri (142)
Montana (33)
Nebraska (29)
Nevada (137)
New Hampshire (83)
New Jersey (3336)
New Mexico (28)
New York (3305)
North Carolina (1589)
North Dakota (8)
Northern California (6234)
Ohio (374)
Oklahoma (23)
Oregon (41)
Pennsylvania (2540)
Puerto Rico (28)
Rhode Island (50)
South America (1112)
South Carolina (83)
South Dakota (2)
Southern California (4942)
Tennessee (203)
Texas (1984)
United States (44426)
Utah (376)
Vermont (1)
Virginia (296)
Washington D.C. (80)
Washington State (1007)
West Virginia (4)
Wisconsin (120)
Wyoming (2)
727,690 Results for "orthogenrx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Avanos Medical, Inc. Announces Agreement To Acquire OrthogenRx, Inc.
Avanos Medical, Inc. (NYSE: AVNS) today announced it has entered into a definitive agreement to acquire OrthogenRx, Inc., an emerging leader in viscosupplementation therapies for the treatment of knee osteoarthritis (OA) pain, for a total consideration of $160 million.
December 13, 2021
·
5 min read
Press Releases
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
March 25, 2026
·
3 min read
Press Releases
NeurAxis, Inc. Announces Preferred Stock Dividend
April 10, 2026
·
3 min read
Press Releases
Milestone Scientific Inc. Completes $2.15 Million Private Placement
April 21, 2026
·
4 min read
Press Releases
LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.
April 21, 2026
·
5 min read
Press Releases
enGene Announces Name Change to enGene Therapeutics Inc.
April 7, 2026
·
8 min read
Press Releases
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
April 7, 2026
·
7 min read
Press Releases
Astrana Health, Inc. Schedules 2026 First Quarter Financial Results Release and Conference Call
April 21, 2026
·
2 min read
Press Releases
Encision Inc. Announces Fiscal 2026 Fourth Quarter and Full Year Results
April 14, 2026
·
2 min read
Business
OrthogenRx Announces 2020 Achievements
OrthogenRx, Inc., a medical device company focused on the development and commercialization of treatments focused on the development and commercialization of treatments for knee pain caused by osteoarthritis (OA), today announced its
January 21, 2021
·
4 min read
1 of 72,769
Next
